Moderna receives Health Canada approval for updated COVID-19 vaccine

Moderna (MRNA) announced that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older. Moderna is on track to deliver the updated vaccine in time for the 2025-2026 vaccination season. All Spikevax pre-filled syringe doses for the Canadian market will now be manufactured domestically, marking the first time Canada’s entire PFS format is produced at home. The drug substance will be produced at Moderna’s new facility in Laval, Quebec, with fill-finish operations completed by Novocol Pharma in Cambridge, Ontario. These Canadian-made doses are expected to be available for this fall.